Zydus Pharmaceuticals (USA) Inc has received tentative approval from the US health regulator to market pregabalin capsules, used for the management of certain kinds of seizures, nerve pain and fibromyalgia.
The company has got tentative approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg, Zydus Cadila said in a BSE filing today.
The drug will be produced at the group’s formulations manufacturing facility in Moraiya, Ahmedabad.
The Zydus group has more than 175 approvals and so far filed over 310 abbreviated new drug applications (ANDAs) since it had started filings in 2003-04.
Zydus Pharmaceuticals Inc is a wholly-owned subsidiary of Cadila Healthcare Ltd.
Shares of Cadila Healthcare, the listed entity of the group, were trading up by 0.41 per cent at Rs 431.15 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.